Conditions: Neoplasms, Ovarian
Keywords: tyrosine kinase inhibitors Primary Peritoneal Carcinoma primary peritoneal cancer ovarian cancer Fallopian Tube Cancer gynecologic cancer anti-angiogenesis pazopanib
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 145
Healthy volunteers: no

Brief summary:
This is a study to determine whether therapy with pazopanib is effective and safe in Asian women with epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has not progressed on first-line chemotherapy.

Detailed description:
This study is an extension study to the VEG110655 study. The parent study, VEG110655, was designed to evaluate whether pazopanib 800 mg daily for 52 weeks will prolong progression free survival (PFS) in women diagnosed with ovarian, fallopian tube or primary peritoneal cancer. These women will have obtained stable disease, a complete remission, or a partial remission after debulking surgery and at least five cycles of chemotherapy (taxane/platinum). This extension study will evaluate safety and efficacy outcomes of pazopanib monotherapy and placebo in an Asian population with the same indication as the parent study.

Arms:
arm 1: experimental medication arm 2: placebo comparator

Interventions: intervention 1: Pazopanib intervention 2: Placebo comparator
Intervention descriptions: intervention 1: Pazopanib 800 mg daily for 24 months intervention 2: Placebo 800 mg daily for 24 months

Protocol document: